A phase I study of the nitroimidazole hypoxia marker SR4554 using (19)F magnetic resonance spectroscopy

BACKGROUND: SR4554 is a fluorine-containing 2-nitroimidazole, designed as a hypoxia marker detectable with (19)F magnetic resonance spectroscopy (MRS). In an initial phase I study of SR4554, nausea/vomiting was found to be dose-limiting, and 1400 mg m(−2) was established as MTD. Preliminary MRS stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, C P, Payne, G S, Oregioni, A, Ruddle, R, Tan, S, Raynaud, F I, Eaton, D, Campbell, M J, Cross, K, Halbert, G, Tracy, M, McNamara, J, Seddon, B, Leach, M O, Workman, P, Judson, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788261/
https://www.ncbi.nlm.nih.gov/pubmed/19935799
http://dx.doi.org/10.1038/sj.bjc.6605425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788261/
https://www.ncbi.nlm.nih.gov/pubmed/19935799
http://dx.doi.org/10.1038/sj.bjc.6605425

Ejemplares similares